Venture Catalysts Exits Pee Safe in $32M OrbiMed-Led Minority Recap

Why It Matters

The deal proves that early bets on India’s underserved women’s hygiene segment can generate outsized returns and accelerate category development, attracting global healthcare investors.

Key Takeaways

• Venture Catalysts earned 9.6× return on Pee Safe investment.
• Pee Safe reached 50,000 retail touchpoints across 100+ cities.
• OrbiMed-led $32M round brings total funding to $45.55M.
• Company growing 45‑50% YoY, expanding omnichannel distribution.
• Early‑stage backing validates underserved women’s hygiene market in India.

Pulse Analysis

India’s women’s hygiene market is transitioning from a fragmented niche to a mainstream consumer category, driven by rising disposable incomes and greater health awareness. Early investors who recognized the gap in organized products have been able to capture both brand equity and distribution advantages. Venture Catalysts’ 2017 entry into Pee Safe exemplifies this foresight, as the startup leveraged its mission‑centric approach to build a portfolio that resonates with modern Indian consumers while addressing a historically underserved need.

Pee Safe’s rapid scaling rests on an aggressive omnichannel strategy that blends traditional retail, e‑commerce, and quick‑commerce platforms. With more than 50,000 offline points across 100+ cities and a consistent 45‑50% year‑on‑year revenue growth, the brand has demonstrated the ability to translate consumer trust into tangible market share. The recent $32 million round, led by OrbiMed, lifts total capital to $45.55 million, earmarked for deeper offline penetration, brand‑led marketing, and stronger presence on fast‑delivery marketplaces, positioning Pee Safe to dominate the personal‑hygiene shelf.

For venture capital, the exit underscores the potency of patient capital in emerging consumer segments. A 9.6× return and a 30.5% XIRR signal that disciplined early‑stage backing can yield both financial upside and strategic validation for later‑stage investors. As global health‑focused firms like OrbiMed increase exposure to Indian consumer health brands, we can expect a wave of follow‑on funding that accelerates product innovation, supply‑chain efficiencies, and cross‑border expansion, further consolidating the market around a few well‑capitalized players.

Deal Summary

Venture Catalysts sold its stake in Pee Safe as part of a secondary transaction in the $32 million OrbiMed‑led funding round. The exit, completed in January 2026, delivered a 9.6× return and over 30% XIRR for the fund. OrbiMed and other investors such as Zerodha and Natco Pharma participated in the round.